Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis
More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should be investigated in strict accordance with the evidence-based medicine principles governing clinical trials (of both original drugs and their analogues) that prove the high efficiency, safety, and tolerabi...
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | Russian |
| Baskı/Yayın Bilgisi: |
IMA-PRESS LLC
2019-12-01
|
| Seri Bilgileri: | Неврология, нейропсихиатрия, психосоматика |
| Konular: | |
| Online Erişim: | https://nnp.ima-press.net/nnp/article/view/1229 |